Uzbekistan and China Expand Pharma Industry Cooperation

Tashkent, Uzbekistan (UzDaily.com) — On April 27, 2026, a meeting was held in Tashkent between the Director of the Agency for the Development of the Pharmaceutical Industry of Uzbekistan, Abdullah Azizov, and representatives of Chinese pharmaceutical companies.

The talks focused on expanding bilateral cooperation across key segments of the industry, including pharmaceutical manufacturing, biotechnology, vaccine production, blood products, active pharmaceutical ingredients (API), generic medicines, and innovative drug development.

During the discussions, the Chinese side presented an overview of its pharmaceutical sector’s position in the global market and outlined approaches to building production chains and advancing innovative drug development. Particular attention was given to opportunities for entering the Uzbek market and prospects for establishing localized production facilities with the participation of foreign investors.

The Uzbek side presented ongoing reforms in the pharmaceutical sector and current development projects aimed at modernizing the industry.

In particular, the BioPharma City pharmaceutical cluster project was introduced, where modern production and research infrastructure is being developed with the participation of both domestic and international investors, aligned with international standards.

The meeting noted that Uzbekistan is considering strengthening its position as a regional pharmaceutical hub.

Among the contributing factors were the country’s strategic geographic location, access to Central Asian and CIS markets, demographic potential, competitive production costs, and existing investment incentives.

Following the talks, both sides confirmed their interest in developing mutually beneficial cooperation and implementing practical joint projects in the pharmaceutical sector.